Ultromics Announces Partnership to Expedite Development of Echo AI Algorithm for Early Detection of Cardiac Amyloidosis
DAIC
JANUARY 15, 2024
Image courtesy of Ultromics milla1cf Mon, 01/15/2024 - 12:54 January 15, 2024 — Ultromics , a patient outcomes-focused AI-driven health technology company with roots at the University of Oxford, UK, has entered into an agreement with Pfizer to support the validation and FDA clearance of its AI-based technology for the detection of cardiac amyloidosis.
Let's personalize your content